Pharmacokinetic assessments of the anti-IL-8 monoclonal antibody, HUMAX-IL8, recorded significant reductions in serum IL-8 levels with good tolerability [66], suggesting a promising approach for psoriasis treatment. This evidence concerns the gene CXCL8 and psoriasis.